The Risks of Health E-Cigarettes: Safety Concerns Arise

Sep.07.2022
The Risks of Health E-Cigarettes: Safety Concerns Arise
Healthy" e-cigarettes, containing vitamins and oils, are growing in popularity but lack safety testing and may have long-term risks.

The so-called health electronic cigarettes are becoming increasingly popular. Unlike regular electronic cigarettes that contain nicotine, these products contain vitamins or essential oils. However, they have caught the attention of the US Food and Drug Administration (FDA).


Healthy electronic cigarettes, also known as 'nutritional supplement diffusers,' encompass a range of products that share a common source found in electronic cigarettes. Unlike traditional cigarettes, electronic cigarettes deliver nicotine to the lungs without combustion or tobacco. This allows for the removal of harmful ingredients such as tobacco tar. Electronic cigarettes work by utilizing energy from a battery to heat liquid, creating an inhalable vapor.


A new line of products aims to use the same inhalation delivery system for various non-nicotine products, including popular vitamins (such as B12 and C), milk thistle, melatonin (a hormone), green tea, and various essential oils. The health e-cigarette company claims that different combinations of these additives can help improve focus, promote sleep, and even aid in weight loss.


Inhaling rather than swallowing these compounds allows for quicker absorption into the bloodstream, hence theoretically making vitamins and supplements more effective when inhaled.


Many of these additives will be familiar as supplements deemed safe for ingestion. However, most lack inhalation safety testing, particularly in regards to potential long-term harm. Because healthy e-cigarettes do not contain nicotine, they have managed to evade regulatory agencies.


The onset of the 2019 outbreak of e-cigarette or vaping product use associated lung injury (or EVALI) in the United States highlighted the importance of detecting ingestion methods. In the initial report of 60 deaths related to EVALI, vitamin E acetate was identified as a key factor causing lung damage in these individuals. Vitamin E is a common food additive, therefore this clearly emphasizes that even well-known healthy substances can have serious consequences on one's health when inhaled.


These devices are quite innovative in the market, and therefore research on their safety is scarce. Administering incorrect patient groups with untested methods could render many benign or beneficial compounds harmful. For example, the benefits of vitamin C are well-known, but using high doses of vitamin C has been shown to increase the risk of death in sepsis patients.


Vitamin B12 is also a popular additive in these devices. B12 injections are highly effective in restoring vitamin levels for those who are deficient. However, there is no evidence to support any benefits for people with normal B12 levels. Additionally, we lack evidence on the safety or efficacy of inhaling B12.


A research conducted in 1967 revealed that inhaling vitamin B12 showed no benefits compared to injecting supplements. However, even at that time, researchers pointed out the potential risk of lung damage.


We can also examine information on components commonly shared with electronic cigarettes to identify potential impacts. Some products offer Vitamin B12 dissolved in vegetable glycerin, a common ingredient in e-liquids. Other products use propylene glycol or a mixture of two liquids. When heated, these components can break down into harmful chemicals known as reactive carbonyl compounds, such as formaldehyde.


These chemicals have been found to damage alveolar macrophages, which are crucial immune cells in the lungs, in a manner that does not depend on the presence of nicotine. Similar findings have been observed in other important airway and immune cells.


Electronic cigarettes that offer essential oils as a healthier option may also be subject to similar issues. They contain a mixture of compounds known as terpenes, as well as other chemicals similar to those found in e-liquids.


According to reports, terpenes have a range of benefits, including anti-cancer, anti-allergy and antibacterial properties, indicating potential benefits of taking these essential oils. However, terpenes can be degraded by heat and may be broken down into harmful compounds when inhaled, which can irritate the respiratory tract and potentially be toxic to cells at higher doses and longer exposure times.


Due to the similarities between electronic cigarettes and health e-cigarettes, these companies are now facing increasingly strict scrutiny from public health institutions. The FDA warns that health e-cigarettes are "unsafe," "ineffective," and "unproven.


Statement:


This article is compiled from third-party information and is intended for industry communication and learning purposes only.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The translation of this article is only intended for industry exchange and research.


Due to the limitations of the translator’s skills, the translated article may not accurately reflect the original text. Please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government's stance and statements on any issues related to domestic, Hong Kong, Macau, Taiwan, and foreign affairs.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us to delete it.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Turning Point Brands Q3 Modern Oral Net Sales Rise 103% to $74.4 Million as Attributable Profit Falls 81%
Turning Point Brands Q3 Modern Oral Net Sales Rise 103% to $74.4 Million as Attributable Profit Falls 81%
Turning Point Brands (TPB) reported third-quarter 2026 Modern Oral net sales of $74.4 million on November 9, up 102.9% year over year and representing 49.2% of consolidated net sales. Total company net sales rose 27.0% to $151.1 million, while net income attributable to TPB declined 81.4% to $3.93 million. The company is expanding the US retail presence of its FRE and ALP nicotine pouch brands and expects its Modern Oral chain-store footprint to grow by more than 70% during 2026. Selling, general and administrative expenses increased 69.1% to $75.3 million, while PMTA-related expenses reached approximately $3.15 million and manufacturing start-up costs totaled about $593,000. ALP plans to open a branded pop-up in New York City's SoHo neighborhood on November 13, alongside a marketing campaign extending into January 2027. TPB owns 50% of ALP but consolidates the venture in its financial statements.
company
Nov.11
Special Report|From CrossBar 20K to 6-Methyl Nicotine KUMI: Two Routes Into U.S. State Vape Directories?
Special Report|From CrossBar 20K to 6-Methyl Nicotine KUMI: Two Routes Into U.S. State Vape Directories?
Several U.S. states have incorporated the September 9, 2020 PMTA filing deadline into eligibility rules for certain vaping products. CrossBar 20K drew attention after appearing on Pennsylvania's 163-entry directory. A broader 2Firsts investigation found that related registration businesses also listed KUMI and CROSSBAR SIX products, with 171 KUMI-related entries across Louisiana, Nebraska and Wisconsin. Corporate records link Scott Silverman to Blue Nine LLC and VR Products I LLC. PMTA compliance expert Mr. K said historical applications and nicotine-analogue products may offer two different approaches to state-directory access.
Regulations
Oct.26
Kelly White Bets on Female Consumers as Nicotine Pouch Competition Intensifies | 2Firsts Interview
Kelly White Bets on Female Consumers as Nicotine Pouch Competition Intensifies | 2Firsts Interview
Swedish nicotine pouch brand Kelly White is building its strategy around adult female consumers. Founder and CEO Sophia Wilsby told 2Firsts that women accounted for around 70% of the brand’s repeat customers on HAYPP in Sweden in 2025. The interview explores female consumer segmentation, product and design differentiation, gender stereotypes, packaging regulation, and how independent brands can compete with global players such as ZYN and VELO while considering funding, partnerships and future ownership options.
Business
Sep.24
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
North Carolina Tightens Vape Product Directory Enforcement, Expands State and Local Powers as Violators Face Fines, Product Seizures and License Suspension or Revocation
North Carolina Tightens Vape Product Directory Enforcement, Expands State and Local Powers as Violators Face Fines, Product Seizures and License Suspension or Revocation
North Carolina has expanded enforcement of its vapor product directory rules, authorizing more state and local law enforcement participation and establishing a task force led by the State Bureau of Investigation. The legislation requires at least one unannounced compliance inspection annually for retailers, distributors and wholesalers handling covered products. Penalties effective October 1, 2026, include civil fines of $500–$750 for a first violation and $1,000–$1,500 for repeated violations within 12 months, along with potential license suspension or revocation. Manufacturers may face penalties of $10,000 per unlisted product. The measures strengthen the product directory system established in 2024.
Regulations
Oct.28
EU TPD Revision May Slip to 2027: Parliament Backs Wider Nicotine Rules by 447 Votes as Commission Impact Assessment Reportedly Receives Negative Opinion
EU TPD Revision May Slip to 2027: Parliament Backs Wider Nicotine Rules by 447 Votes as Commission Impact Assessment Reportedly Receives Negative Opinion
On Nov 12, 2026, the European Parliament adopted a resolution on implementing Europe’s Beating Cancer Plan by 447 votes to 66, with 91 abstentions, urging the European Commission to speed up revisions to the Tobacco Products Directive (TPD) and Tobacco Advertising Directive (TAD). Parliament called for broader regulation of e-cigarettes, heated tobacco, nicotine pouches and other emerging nicotine products, proposing measures on packaging, health warnings, flavors, ingredient reporting, online age verification, digital marketing and premarket health impact assessments. EUNews and others reported that the Commission’s Regulatory Scrutiny Board (RSB) issued a negative opinion on the revisions’ impact assessment on Nov 9. The Commission had scheduled the initiative for December 2026, but the reported setback could push the legislative proposal into 2027. No revised official timetable has been announced, and Parliament’s resolution does not amend existing EU law.
Regulations
Nov.19